Skip to Navigation Skip to Search Skip to Content
Search All Centers

What Have We Learned About Selinexor (Xpovio)?

Published on May 11, 2021

Expert Shares New Learnings About Selinexor (Xpovio)

In this episode of our Multiple Myeloma Ask the Expert series, Patient Power co-founder and patient advocate Andrew Schorr meets with Dr. Clifton Mo, MD, Medical Oncologist and Director of Autologous Stem Cell Transplantation for Multiple Myeloma at the Dana-Farber Cancer Institute, to discuss the trajectory of the drug selinexor (Xpovio) for the treatment of multiple myeloma. They will discuss new learnings about the drug from recent clinical trials, who is eligible for treatment, and more.

Recommended Programs: